Our Company: Developing Oncology Therapeutics to Improve Cancer Care

Our lead therapeutic candidate, PCM-075, provides us the opportunity to bring a first-in-class PLK1 inhibitor to the market for the treatment of patients with acute myeloid leukemia (AML). The pharmacokinetic and pharmacodynamic properties of PCM-075 may provide a more selective approach for targeting the rapid mitosis that is characteristic of AML, as well as avoid some of the debilitating toxicities seen with standard chemotherapy drugs.

Highlights

Oncology Therapeutics, Precision Medicine in cancer - AML Ribbon
Initiation of Phase 1b/2 Clinical Trial in Patients with Acute Myeloid Leukemia (AML)

A Phase 1b/2 clinical trial of PCM-075 in combination with low-dose cytarabine or decitabine in patients with AML for exploration of the safety, tolerability, dose and scheduling, and anti-tumor activity. Phase 1b is an open label dose escalation trial of PCM-075 to determine a recommended combination and clinical treatment dose for the Phase 2 open-label continuation trial.

Oncology Therapeutics, Precision Medicine in cancer - NEXTCOLLECT Box
Coming Soon NextCollect

NextCollect is a first of its kind, proprietary urine collection and DNA preservation system. By housing the preservative solution in the reservoir cap, we have created the first ever automated DNA stabilizing device for urine collection. For more information, please email bd@trovagene.com.

Oncology Therapeutics, Precision Medicine in cancer - LD Micro
19th Annual Rodman & Renshaw Global Investment Conference

Trovagene CEO, Bill Welch, will be presenting at the conference on Tuesday, September 12th, at 5:05 pm EDT at the Lotte New York Palace Hotel in New York City. The presentation will be webcast live at http://wsw.com/webcast/rrshq27/trov and a replay of the presentation will be available and archived for 90 days.